NCT02612662 - A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2015

Primary Completion Date

November 4, 2017

Study Completion Date

August 29, 2025

Conditions

Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

AZD4076

Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

DRUG

Placebo

Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Trial Locations (1)

Research Site, Brooklyn